secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001171843-25-001760
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus reports FY2024 net loss $69.9M; cuts workforce 57%, appoints new CFO
----------------------------------------------------------------------------

- Net loss for 2024 was $69.9M ($0.38/share) vs $72.8M ($0.44) in 2023; revenue $6.2M down from $18.1M.
- Cash and marketable securities $122.6M at Dec 31, 2024; ATM program terminated.
- Workforce reduced by 57% in Q1 2025, retaining 19 employees; expects $11-13M restructuring charge.
- Tuan Nguyen appointed CFO effective March 28, 2025, replacing David Hastings; General Counsel and CMO departures.
- Moderna U.S. LNP patent trial scheduled for Sept 2025; Pfizer/BioNTech claim construction ruling pending; international lawsuits filed March 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325001760/0001171843-25-001760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325001760/f8k_032725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer